Drugnews

About Drugnews

Drugnews is a biotech and pharmaceutical business-analysis media platform.

We do not stop at headlines. We interpret whether clinical evidence, company strategy, licensing activity, manufacturing risk, and capital-market signals can change the business value of a company or a sector.

Editorial Standard

How we write

01Evidence first

We prioritize clinical data, regulatory progress, company disclosures, licensing terms, and verifiable sources.

02Business judgment next

Mechanism, efficacy, safety, CMC, competition, payment structure, and market positioning are interpreted together.

03Separate facts and views

We try to distinguish disclosed facts, reasonable inference, and unresolved uncertainty.

04Citable by design

Website articles preserve titles, dates, canonical URLs, references, and citation guidance for long-term use.

What readers can expect

Drugnews serves biotech investors, industry professionals, BD and IR teams, and readers learning how to interpret biotech companies.

Company research

Products, platforms, competitors, clinical milestones, cash runway, and market positioning organized into trackable company judgment.

Clinical and CMC risk

Endpoints, safety, manufacturing, supply chain, and regulatory signals interpreted as commercial evidence.

BD and licensing

Upfront payments, milestones, royalties, options, territory rights, and deal risk explained through buyer and seller incentives.

Valuation and capital markets

rNPV, SOTP, peak sales, peer comparisons, and capital-market sentiment used to explain why assets are repriced.

Collaboration boundaries

Drugnews may work with companies on feature articles, interviews, IR narratives, event recaps, and company-service content. Collaboration must be based on public information, company-approved disclosure, and professional research frameworks.

01

No non-public material information

Collaboration content should not include undisclosed material information, insider information, or unauthorized details.

02

No market-performance promise

Our content work aims to improve understanding and communication quality. It does not promise share-price, volume, fundraising, or investor behavior outcomes.

03

Professional judgment remains

Even in collaboration content, Drugnews keeps basic fact-checking, risk disclosure, and industry context.

About Drugnews

Drugnews turns clinical data, company strategy, licensing activity, and capital-market signals into clear business judgment for biotech and pharmaceutical readers.

We cover company research, clinical and CMC risks, licensing and BD, valuation, and capital-market signals. The goal is not to summarize news, but to explain which evidence can change business value.

Team

Two biomedical PhDs translating science into business judgment.

Drugnews is built by Dr. Jo-Fan Pan and Dr. Chuan-Sheng Lin, combining clinical medicine, biotech R&D, business development, and capital-market perspectives. The editorial goal is to turn biotech information into research material readers can inspect, compare, and track.

Founder / Editor-in-Chief

Dr. Jo-Fan Pan

PhD, University of Manchester; BSN, National Taiwan University. Leads Drugnews topic selection, business-analysis frameworks, long-form structure, and reader communication.

Partner / Scientific Strategy

Dr. Chuan-Sheng Lin

Biomedical dual-PhD background with more than 15 years across the biotech and pharmaceutical R&D value chain, helping review scientific evidence, technical barriers, and development risk.